Polymeric Nanomaterials for Islet Targeting and Immunotherapeutic Delivery
Source abstract
Abstract
Here we report a proof-of-concept for development of pancreatic islet-targeting nanoparticles for immunomodulatory therapy of autoimmune type 1 diabetes. Modified with a unique islet-homing peptide, these polymeric nanomaterials exhibit 3-fold greater binding to islet endothelial cells and a 200-fold greater anti-inflammatory effect through targeted islet endothelial cell delivery of an immunosuppressant drug. Our findings also underscore the need to carefully tailor drug loading and nanoparticle dosage to achieve maximal vascular targeting and immunosuppression.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · Adenosine and Purinergic Signaling · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Vascular Biology Program, Departments of Pathology and Surgery, Children’s Hospital and Harvard Medical School, Boston, Massachusetts, United States
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, United States
Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States
School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, United States
References (27)
Show source-provided references
1. Shi J. · Nano Lett. · 2010 · 10 · 322310.1021/nl102184c ↗
2. Peer D. · Nat. Nanotechnol. · 2007 · 2 · 75110.1038/nnano.2007.387 ↗
3. Eizirik D. L. · Nat. Rev. Endocrinol. · 2009 · 5 · 21910.1038/nrendo.2009.21 ↗
4. In’t Veld P. · Diabetes · 2009 · 58 · 125710.2337/db09-0345 ↗
5. Ferrannini E. · Diabetes · 2010 · 59 · 67910.2337/db09-1378 ↗
6. Sosenko J. M. · Diabetes Care · 2008 · 31 · 52810.2337/dc07-1459 ↗
7. Sosenko J. M. · Diabetes Care · 2007 · 30 · 3810.2337/dc06-1615 ↗
8. Waldron-Lynch F. · Nat. Rev. Drug Discovery · 2011 · 10 · 43910.1038/nrd3402 ↗
9. Feutren G. · Lancet · 1986 · 2 · 11910.1016/S0140-6736(86)91943-4 ↗
10. Silverstein J. · N. Engl. J. Med. · 1988 · 319 · 59910.1056/NEJM198809083191002 ↗
11. Parving H. H. · Diabetes Care · 1999 · 22 · 47810.2337/diacare.22.3.478 ↗
12. Bingley P. J. · Diabetes Care · 2008 · 31 · 14610.2337/dc07-0103 ↗
13. Berchtold P. · Schweiz. Med. Wochenschr. · 1996 · 126 · 1603
14. Cheng J. · Biomaterials · 2007 · 28 · 86910.1016/j.biomaterials.2006.09.047 ↗
15. Lu J. M. · Expert Rev. Mol. Diagn. · 2009 · 9 · 32510.1586/erm.09.15 ↗
16. Yao V. J. · Am. J. Pathol. · 2005 · 166 · 62510.1016/S0002-9440(10)62283-3 ↗
17. Decuzzi P. · Pharm. Res. · 2009 · 26 · 23510.1007/s11095-008-9697-x ↗
18. Gu F. · Proc. Natl. Acad. Sc.i U.S.A. · 2008 · 105 · 258610.1073/pnas.0711714105 ↗
19. Uno S. · Diabetologia · 2007 · 50 · 59610.1007/s00125-006-0569-9 ↗
20. Sun W. Y. · Am. J. Pathol. · 2010 · 177 · 43610.2353/ajpath.2010.091016 ↗
21. Chen X. L. · Inflamm Res · 2009 · 58 · 51310.1007/s00011-009-0017-7 ↗
22. Weber C. · J. Immunol. · 1995 · 155 · 44510.4049/jimmunol.155.1.445 ↗
23. Mitragotri S. · Nat. Mater. · 2009 · 8 · 1510.1038/nmat2344 ↗
24. Kim J. · Nano Lett. · 2010 · 11 · 69410.1021/nl103812a ↗
25. Kumar P. · Expert Rev. Mol. Med. · 2009 · 11 · e1910.1017/S1462399409001112 ↗
26. Mathews V. · Diabetes · 2004 · 53 · 9110.2337/diabetes.53.1.91 ↗
27. Liu M. · J. Cell Mol. Med. · 2008 · 12 · 115510.1111/j.1582-4934.2008.00288.x ↗